<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143102</url>
  </required_header>
  <id_info>
    <org_study_id>305</org_study_id>
    <nct_id>NCT02143102</nct_id>
  </id_info>
  <brief_title>Non-invasive Computer-Aided Phenotyping of Vasculopathy</brief_title>
  <acronym>Q-CAMP</acronym>
  <official_title>vascuCAP: Non-invasive Computer-Aided Phenotyping of Vasculopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elucid Bioimaging Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elucid Bioimaging Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators use MRI and/or CT to evaluate the extent, as well as, the structure,
      composition, and functional aspects of atherosclerotic plaques in human carotid and femoral
      arteries in patients scheduled to undergo an endarterectomy of the aforementioned vascular
      beds as part of their routine clinical care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that in vivo MRI and/or CT examinations of patients, when
      suitably acquired and analyzed with the vascuCAP™ analysis software, can provide a
      sufficiently accurate profile of plaque characteristics to provide an objective basis for
      patient management. Study subjects include patients undergoing endarterectomies to mitigate
      their clinical risk or symptoms for conditions including stroke, claudication, and critical
      limb ischemia. The endarterectomy specimens removed at surgery will allow a direct comparison
      between the MRI information obtained prior to the surgery and the histopathological analyses
      of the arterial specimens. The vascuCAP™ measurements of structural and functional features
      of the arterial wall will be performed in patients undergoing endarterectomy. Measured
      results will be compared in a blinded fashion with histology to assess performance of plaque
      profiling and build a pilot prediction model for risk scoring.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 30, 2017</completion_date>
  <primary_completion_date type="Actual">March 14, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth.</measure>
    <time_frame>Assessed on tissue samples collected within 30 days of non-invasive imaging</time_frame>
    <description>Performance of measurements was assessed by estimating the bias (the difference between the measurement and histology)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement Bias of Lipid-rich Necrotic Core Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth.</measure>
    <time_frame>Assessed on tissue samples collected within 30 days of non-invasive imaging</time_frame>
    <description>Performance of measurements was assessed by estimating the bias (the difference between the measurement and histology)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">125</enrollment>
  <condition>Carotid Atherosclerosis</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Training set</arm_group_label>
    <description>Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testing set</arm_group_label>
    <description>Data from subjects in the testing set will be used to assess the study endpoints.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      After endarterectomy during surgery, the excised plaque specimens will be sent to the
      hospital's pathology lab to be analyzed.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals must meet one of the following inclusion criteria in order to be eligible to
        participate in the study:

          -  Case subjects will be patients with documented carotid atherosclerosis, scheduled for
             magnetic resonance or CT angiography and subsequent elective endarterectomy with 30
             days of enrollment in the study

          -  Case subjects will be patients with peripheral arterial disease (PAD) with clinical
             symptoms, scheduled for magnetic resonance or CT angiography and indicated
             endarterectomy of diseased areas of femoral arteries within 30 days of enrollment in
             the study
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals must meet one of the following inclusion criteria in order to be eligible to
        participate in the study:

          -  Case subjects will be patients with documented carotid atherosclerosis, scheduled for
             magnetic resonance or CT angiography and subsequent elective endarterectomy with 30
             days of enrollment in the study

          -  Case subjects will be patients with peripheral arterial disease (PAD) with clinical
             symptoms, scheduled for magnetic resonance or CT angiography and indicated
             endarterectomy of diseased areas of femoral arteries within 30 days of enrollment in
             the study

        Exclusion Criteria:

          -  Subjects with claustrophobia or inability to tolerate prior MRI studies.

          -  Subjects with metal implants that are not MRI compatible (LSU detailed checklist to be
             attached) including: Subjects with any type of bio-implant activated by mechanical,
             electronic, or magnetic means (e.g. cochlear implants, pacemakers, neurostimulators,
             biostimulators, electronic infusion pumps, etc.). Subjects with any type of
             ferromagnetic bio-implant that could potentially be displaced or damaged, such as
             aneurysm clips, metallic skull plates, etc.

          -  Subjects with a history of kidney disease or dialysis that are unable to receive
             intravenous gadolinium contrast material.

          -  Female subjects. A urine pregnancy test will be required of all female subjects of
             childbearing potential prior to inclusion in this study. Pregnant or nursing females
             will be excluded from the study.

          -  Subjects who cannot adhere to the experimental protocol.

          -  Subjects allergic to contrast material.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J. Buckler, M.S.</last_name>
    <role>Study Director</role>
    <affiliation>Elucid Biomaging Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Jefferson Medical Center</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU ILH</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>May 15, 2014</study_first_submitted>
  <study_first_submitted_qc>May 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2014</study_first_posted>
  <results_first_submitted>September 7, 2017</results_first_submitted>
  <results_first_submitted_qc>November 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 6, 2018</results_first_posted>
  <last_update_submitted>November 7, 2017</last_update_submitted>
  <last_update_submitted_qc>November 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carotid Artery Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 12, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02143102/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 8, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT02143102/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Development Set</title>
          <description>Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers.</description>
        </group>
        <group group_id="P2">
          <title>Testing Set</title>
          <description>Data from subjects in the testing set will be used to assess the study endpoints.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Development Set</title>
          <description>Data from subjects in the training set will be utilized to further develop the vascuCAP measurements.</description>
        </group>
        <group group_id="B2">
          <title>Testing Set</title>
          <description>Data from subjects in the testing set will be used to assess the study endpoints.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="86"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.2" spread="11"/>
                    <measurement group_id="B2" value="66.6" spread="10.1"/>
                    <measurement group_id="B3" value="66.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth.</title>
        <description>Performance of measurements was assessed by estimating the bias (the difference between the measurement and histology)</description>
        <time_frame>Assessed on tissue samples collected within 30 days of non-invasive imaging</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testing Set</title>
            <description>Data from subjects in the testing set will be used to assess the study endpoints.</description>
          </group>
          <group group_id="O2">
            <title>Full</title>
            <description>Pooled results for final estimation</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth.</title>
          <description>Performance of measurements was assessed by estimating the bias (the difference between the measurement and histology)</description>
          <units>mm2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" lower_limit="-1.75" upper_limit="0.41"/>
                    <measurement group_id="O2" value=".07" lower_limit="-.22" upper_limit=".42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Measurement Bias of Lipid-rich Necrotic Core Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth.</title>
        <description>Performance of measurements was assessed by estimating the bias (the difference between the measurement and histology)</description>
        <time_frame>Assessed on tissue samples collected within 30 days of non-invasive imaging</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testing Set</title>
            <description>Data from subjects in the testing set will be used to assess the study endpoints.</description>
          </group>
          <group group_id="O2">
            <title>Full</title>
            <description>Pooled results for final estimation</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement Bias of Lipid-rich Necrotic Core Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth.</title>
          <description>Performance of measurements was assessed by estimating the bias (the difference between the measurement and histology)</description>
          <units>mm2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" lower_limit=".12" upper_limit="2.51"/>
                    <measurement group_id="O2" value=".87" lower_limit="-.18" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from time of enrollment through endarterectomy procedure, an average of 1 month</time_frame>
      <desc>The study protocol was written to ensure that the study have no effect on either diagnosis or treatment of enrollees.</desc>
      <group_list>
        <group group_id="E1">
          <title>Development Set</title>
          <description>Data from subjects in the training set will be utilized to further develop the vascuCAP measurements.</description>
        </group>
        <group group_id="E2">
          <title>Testing Set</title>
          <description>Data from subjects in the testing set will be used to assess the study endpoints.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Andrew J. Buckler</name_or_title>
      <organization>Elucid Bioimaging</organization>
      <phone>978-468-0508</phone>
      <email>andrew.buckler@elucidbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

